Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision loss due to photoreceptor cell death. Comprised of a diverse team of pioneering scientists, Vedere Bio II is discovering and developing next generation ocular gene therapies to increase the quality of vision restoration and preservation for large, underserved indications.
| Headquarters | Cambridge, MA |
| Website | www.vederebio.com |
| Pipeline Status | Preclinical |
| @VedereBio | |
| Vedere Bio II |